Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental HIV therapy aims to train body to fight virus

NCT ID NCT06430905

First seen Oct 31, 2025 · Last updated May 18, 2026 · Updated 26 times

Summary

This study tested two experimental treatments, HB-502 and HB-501, designed to teach the immune system to recognize and attack HIV. It involved 30 adults with HIV who were already on stable antiretroviral therapy (ART). The goal was to check if the treatments are safe and can trigger an immune response against HIV. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Beth Israel Deaconness Medical Center (BIDMC)

    Boston, Massachusetts, 02215, United States

  • Brigham and Women´s Hospital

    Boston, Massachusetts, 02115, United States

  • Orlando Immunology Center (OIC)

    Orlando, Florida, 32803, United States

  • Perelman Center for Advanced Medicine at the Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • The Hope Clinic at Emory University

    Decatur, Georgia, 30030, United States

Conditions

Explore the condition pages connected to this study.